Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting
05 December 2012 - 6:45AM
Business Wire
Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned
subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”),
today announced that Biovest will present at the Lymphoma
Coalition’s annual patient advocacy event leading up to the
American Society of Hematology (ASH) Annual Meeting in Atlanta,
Dec. 8-11. Biovest will provide an update on BiovaxID™, its
late-stage, personalized cancer vaccine for the treatment of
non-Hodgkin’s lymphoma, which has been featured in a series of
recent web-based articles by lymphoma patient advocates reporting
on the urgent, unmet need for additional consolidation therapeutic
options for lymphoma patients concerned with safety and
side-effects.
BiovaxID Presentation
Details:
Event: Lymphoma Coalition Presentation & Reception
Evening
Day/Time: Thursday, December 6th at 4:30 pm EST
Place: Marriott Perimeter Centre, 246 Perimeter Centre
Parkway NE, Atlanta, Georgia
For More Information: www.lymphomacoalition.org
To review articles by lymphoma patient advocates reporting on
BiovaxID and the unmet need for additional consolidation
therapeutic options, please visit the following publication
links:
-
AnnArbor.Comhttp://www.annarbor.com/health/patients-fight-back-when-the-fda-refuses-to-review-a-new-cancer-therapy/
-
LymphomaInfo.Nethttp://www.lymphomainfo.net/lifestyle/non-hodgkins/follicular/sign-the-petition-to-bring-the-lymphoma-vaccine-to-market
To request a meeting with Biovest at this Lymphoma Coalition
event or at ASH, please contact Douglas Calder at 813-507-2558 or
dwcalder@biovest.com.
About Biovest International,
Inc.
Biovest International, Inc. develops active immunotherapies
(cancer vaccines) which treat and diminish the aggressiveness of
B-cell non-Hodgkin’s lymphoma, a cancer of the immune system. The
Company’s lead personalized cancer vaccine product candidate,
BiovaxID™, has been evaluated in three clinical trials conducted in
collaboration with the U.S. National Cancer Institute (NCI)
demonstrating that BiovaxID increases the duration of cancer
remission following chemotherapy and induces immune responses which
correlate highly with long-term survival. Biovest is currently in
the process of pursuing European and Canadian marketing approvals
for BiovaxID.
Headquartered in Tampa, Florida with its bio-manufacturing
facility based in Minneapolis, Minnesota, Biovest is
publicly-traded on the OTCQB™ Market with the stock-ticker symbol
“BVTI”, and is a majority-owned subsidiary of Accentia
Biopharmaceuticals, Inc. (OTCQB: “ABPI”).
For further information, please visit:
http://www.biovest.com
Forward-Looking
Statements:
Statements in this press release that are not strictly
historical in nature constitute "forward-looking statements.”
Such statements include, but are not limited to, statements
about Biovest and its product candidate, BiovaxID™ and any other
statements relating to products, product candidates, product
development programs, the FDA, the EMA, Health Canada or clinical
study process including the commencement, process, or completion of
clinical trials or the regulatory process. Such statements
may include, without limitation, statements with respect to the
Company's plans, objectives, expectations and intentions, and other
statements identified by words such as "may," "could," "would,"
"should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans," or similar expressions. In particular (and
without limitation), statements regarding the timing of anticipated
filing of a Marketing Authorization Application for BiovaxID with
the EMA or a New Drug Submission for BiovaxID with Health Canada,
pre-filing meetings with the FDA or other jurisdictions and/or
commercial plans reflect current expectations but are subject to
inherent risks of delay in compilation and finalization of all
components of the licensing application. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other factors that may cause the actual results of Biovest to be
materially different from historical results or from any results
expressed or implied by such forward-looking statements.
These factors include, but are not limited to, risks and
uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or
delays in obtaining regulatory approval for product candidates;
competition from other pharmaceutical or biotechnology companies;
and the additional risks discussed in filings with the Securities
and Exchange Commission. All forward-looking statements are
qualified in their entirety by this cautionary statement, and
Biovest undertakes no obligation to revise or update this news
release to reflect events or circumstances after the date
hereof. The product names used in this statement are for
identification purposes only. All trademarks and registered
trademarks are the property of their respective owners.